Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Kiran Vemuri"'
Autor:
Basma G. Eid, Thikryat Neamatallah, Lenah S. Binmahfouz, Amina M. Bagher, Abdulmohsin J. Alamoudi, Hibah Mubarak Aldawsari, Abeer Hanafy, Atif Hasan, Hany M. El-Bassossy, Ashraf B. Abdel-Naim, Kiran Vemuri, Alexandros Makriyannis
Publikováno v:
Biomolecules & Biomedicine, Vol 23, Iss 6 (2023)
Metabolic syndrome (MetS) is a combination of metabolic disorders that can predispose individuals to benign prostatic hyperplasia (BPH). The inhibition of the cannabinoid 1 (CB1) receptor has been used to treat metabolic disorders in animal models. T
Externí odkaz:
https://doaj.org/article/bf26427057b54474941cbe5c795699b5
Autor:
Basma G. Eid, Thikryat Neamatallah, Abeer Hanafy, Hany M. El-Bassossy, Lenah Binmahfouz, Hibah M. Aldawsari, Atif Hasan, Gamal Abd El-Aziz, Kiran Vemuri, Alexandros Makriyannis
Publikováno v:
Molecules, Vol 29, Iss 4, p 902 (2024)
The authors wish to make the following changes to the paper [...]
Externí odkaz:
https://doaj.org/article/f8661fcea97a4f9e86132aafca99a8d5
Autor:
Basma G. Eid, Thikryat Neamatallah, Abeer Hanafy, Hany M. El-Bassossy, Lenah Binmahfouz, Hibah M. Aldawsari, Atif Hasan, Gamal Abd El-Aziz, Kiran Vemuri, Alexandros Makriyannis
Publikováno v:
Molecules, Vol 26, Iss 4, p 866 (2021)
The role of cannabinoid receptors in nephropathy is gaining much attention. This study investigated the effects of two neutral CB1 receptor antagonists, AM6545 and AM4113, on nephropathy associated with metabolic syndrome (MetS). MetS was induced in
Externí odkaz:
https://doaj.org/article/92c098f9897b48249f94b5e62c63f2c0
Autor:
Basma G. Eid, Thikryat Neamatallah, Abeer Hanafy, Hany M. El-Bassossy, Hibah M. Aldawsari, Kiran Vemuri, Alexandros Makriyannis
Publikováno v:
Medicina, Vol 56, Iss 11, p 573 (2020)
Background and Objectives: Insulin resistance (IR) is a serious condition leading to development of diabetes and cardiovascular complications. Hyper-activation of cannabinoid receptors-1 (CB1) has been linked to the development of metabolic disorders
Externí odkaz:
https://doaj.org/article/9d4a1a64a4ac4809880093e4aea18cb2
Autor:
Hailey, Cuddihey, Jean-Baptiste, Cavin, Catherine M, Keenan, Laurie E, Wallace, Kiran, Vemuri, Alexandros, Makriyannis, Wallace K, MacNaughton, Keith A, Sharkey
Publikováno v:
American journal of physiology. Gastrointestinal and liver physiology. 323(3)
The endocannabinoid system of the gastrointestinal tract is involved in the control of intestinal barrier function. Whether the cannabinoid 1 (CB
Autor:
Hailey Cuddihey, Jean-Baptiste Cavin, Catherine M. Keenan, Laurie E. Wallace, Kiran Vemuri, Alexandros Makriyannis, Wallace K. MacNaughton, Keith A. Sharkey
Publikováno v:
American Journal of Physiology-Gastrointestinal and Liver Physiology. 323:G219-G238
The endocannabinoid system of the gastrointestinal tract regulates homeostasis by acting as brake on motility and secretion. Here we show that when exposed to a high fat diet, intestinal permeability is increased and activation of the CB1 receptor on
Autor:
Dimitris Spyridakos, Niki Mastrodimou, Kiran Vemuri, Thanh C. Ho, Spyros P. Nikas, Alexandros Makriyannis, Kyriaki Thermos
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 1; Pages: 240
Oxidative stress, neurodegeneration, neuroinflammation, and vascular leakage are believed to play a key role in the early stage of diabetic retinopathy (ESDR). The aim of this study was to investigate the blockade of cannabinoid receptor 1 (CB1R) and
Autor:
Dalal A. Alkhelb, Andre Kirunda, Ioannis Papanastasiou, Shan Jiang, Christos Iliopoulos‐Tsoutsouvas, Alexander Zvonok, Spyridon P. Nikas, Kiran Vemuri, Alexandros Makriyannis, Rajeev I. Desai
Publikováno v:
The FASEB Journal. 36
Autor:
Shakiru O. Alapafuja, Shan Jiang, Ani S. Zakarian, Brian D. Kangas, Jack Bergman, Alexandros Makriyannis, Kiran Vemuri, Spyros P. Nikas
Publikováno v:
J Pharmacol Exp Ther
Despite a growing acceptance that withdrawal symptoms can emerge following discontinuation of cannabis products, especially in high-intake chronic users, there are no Food and Drug Administration (FDA)–approved treatment options. Drug development h
Autor:
Alexandros Makriyannis, Raymond C. Stevens, Yiran Wu, Kiran Vemuri, Laura M. Bohn, Zhi-Jie Liu, Tian Hua, Travis W. Grim, Robert B. Laprairie, Jo-Hao Ho, Edward L. Stahl, Anisha Korde
Publikováno v:
Molecular Pharmacology. 96:619-628
Cannabinoid receptor 1 (CB1) is a potential therapeutic target for the treatment of pain, obesity and obesity-related metabolic disorders, and addiction. The crystal structure of human CB1 has been determined in complex with the stabilizing antagonis